The XABCL generated from the TNBC biopsy resulted in a lymphocytic tumor; XABCL-LCL was CD19+, CD20+, CD21−, and CD38+, an activated germinal center B-cell phenotype. The gene discussed is CD19; the disease is lymphoid neoplasm.